Health
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
PRINCETON, N.J., December 05, 2025--BMS's Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"Product image for download (Photo: Bristol Myers Squibb)","displaySize":"","headline":null,"caption":"Product image for download (Photo: Bristol Myers Squibb)","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/bb2286ed2f0bcc352700e20a2b4d6884"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3rAsS3VRnZKisDaBjcZAcw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bb2286ed2f0bcc352700e20a2b4d6884","width":480,"height":320}},"lazy":false},{"type":"image","alt":"MZL Infographic","displaySize":"","headline":null,"caption":"MZL Infographic","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":323,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/9813852af5278483754e1d5bcbdf8b6b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/F0QW9.MOU2dovymwIc5.Zw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTk1MTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9813852af5278483754e1d5bcbdf8b6b","width":323,"height":480}}},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/4a1022eb6c0c1a473a9ea5591e5c4566"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5u9JmjY0gpr2KVs3i6ax3w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4a1022eb6c0c1a473a9ea5591e5c4566","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ddlSUgT3B3bHWXR234eywA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/4a1022eb6c0c1a473a9ea5591e5c4566","width":1200,"height":165}}},{"type":"text","content":"In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a consistent safety profile","length":149,"tagName":"p","attribs":{}},{"type":"text","content":"Breyanzi is now the only CAR T cell therapy approved by the FDA for five cancer types, the most of any CD19-directed CAR T cell therapy","length":135,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., December 05, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (N...